DiscoverIPO

Braveheart Bio, Inc.

expected
Aug 5, 2026
status
Expected
proposed ticker
BRVE
Industry
Pharmaceutical Preparations
Headquarters
United States
Incorporated in
DE
Exchange
NASDAQ
Price range
$15.00 – $17.00
Shares offered
18.8M shares
Offer size
$345M
Underwriters
GS, JEFFER, TDSEC, STFL, CFCO

Overview

Business overview

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) aimed at treating obstructive HCM (oHCM) and non-obstructive HCM (nHCM). BHB-1893 was initially discovered by Jiangsu Hengrui Pharmaceuticals Co., Ltd. and is being developed to improve treatment options for HCM patients by enhancing therapeutic profiles while minimizing complexities in prescribing.

Revenue model

>Braveheart Bio, Inc. does not currently generate revenue from its operations, as it is still in the clinical trial phase with its lead product candidate BHB-1893.

Competitive strengths

  • Developing a next-generation treatment for HCM with potentially improved efficacy and safety profiles than existing therapies.
  • Exclusive licensing agreement for BHB-1893 with Jiangsu Hengrui Pharmaceuticals, leveraging prior development work conducted in China.
  • Focus on addressing significant unmet medical needs in the cardiovascular disease space.

Risk factors

  • Uncertainties inherent in the clinical trial process, including the risk of failure in future trials.
  • Regulatory approval risks, including the need for compliance with various regulations and guidelines.
  • Market adoption challenges due to competition from existing therapies and potential limitations of BHB-1893.

Use of proceeds

The use of proceeds from the offering is not specified in the provided text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Braveheart Bio, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 5, 2026. Shares are expected to be offered at $15.00 – $17.00, with 18.8M shares on offer, for a total offer size of $345M. The proposed ticker is BRVE. Underwriters on the deal include GS, JEFFER, TDSEC, STFL, CFCO. Braveheart Bio, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Braveheart Bio, Inc. has filed 4 times, starting with a S1/A on Jul 30, 2026.

Frequently asked questions

When is Braveheart Bio, Inc. expected to go public?

Braveheart Bio, Inc. is expected to list on Aug 5, 2026.

What exchange will Braveheart Bio, Inc. list on?

Braveheart Bio, Inc. is listing on NASDAQ.

How much is Braveheart Bio, Inc. raising in its IPO?

Braveheart Bio, Inc.'s offering is expected to raise $345M.

What is Braveheart Bio, Inc.'s ticker symbol?

Braveheart Bio, Inc.'s proposed ticker is BRVE.

Where this data comes from

New York Stock Exchange listings data. Retrieved Aug 1, 2026.

View the original filing on NYSE →

All filings for this company

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.

We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy